Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy

Clonal cytogenetic evolution with additional chromosomal abnormalities (ACAs) in chronic myelogenous leukemia (CML) is generally associated with decreased response to tyrosine kinase inhibitor (TKI) therapy and adverse survival. Although ACAs are considered as a sign of disease progression and have...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Wang, Wei, Cortes, Jorge E., Tang, Guilin, Khoury, Joseph D., Wang, Sa, Bueso-Ramos, Carlos E., DiGiuseppe, Joseph A., Chen, Zi, Kantarjian, Hagop M., Medeiros, L. Jeffrey, Hu, Shimin
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2016
Matèries:
Myeloid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4915795/
https://ncbi.nlm.nih.gov/pubmed/27006386
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2016-01-690230
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars